Talk:Novavax COVID-19 vaccine

Efficacy in South-Africa not equal to efficacy against Beta variant
Added template. At the time of the study, there was still some non-Beta variants in SA. Therefore efficacy in SA is not efficacy against BETA. Please read the articles in depth to see the differences. Even some scientist seems confused. If not corrected, will do it myself. Don't want to start an edit war.

--Tech-ScienceAddict (talk) 23:37, 30 June 2021 (UTC)

Study seems to be against immunodeficient HIV patients and not the general population, so the results should not be taken at face value. No vaccine expected to have much over 50% efficacy in immunodeficient individuals. DustWolf (talk) 06:07, 3 October 2022 (UTC)

Technology, use of lipid nanoparticle
The article reads "The spike proteins are harvested and assembled onto a synthetic lipid nanoparticle ..." and I want to make sure the way I read this is correct: the proteins are presented on the outside of the LNPs, so they do not have to enter any cells, unlike the LNPs with mRNA that have to enter cells. Is that correct?

The text would differ only in one letter, changing "onto" to "into" which could easily be a typo.

--94.216.247.167 (talk) 02:09, 23 January 2022 (UTC)

Economics section removed?
I have been reading the vaccine pages regularly (I am not a Wikipedia editor - I made an account to leave this message), and am wondering why the Economics section of this page was removed (it appears to have been removed by someone as "not news")? It seems this information is important to providing sociopolitical and economic information about access to vaccines, which certainly holds long-term importance as we continue to understand the long-term efficacy (or lack thereof) from vaccine usage - or lack of access to it.

The other major vaccine pages all have the same Economics section removed from this page, so it almost feels like a bit of prejudice against this particular biomanufacturer, which seems odd. Again, I am not a regular Wikipedia editor - but as someone who reads the vaccine pages weekly, it feels as if it is missing critical information to understand the application and adoption of this vaccine. Just my two cents! Disco8Ball (talk) 14:32, 1 March 2022 (UTC)

EMA Approval of Nuvaxovid
Nuvaxovid XBB.1.5 is now authorised across the EU. The European Commission granted a marketing authorisation on 31 October 2023. Source: https://www.ema.europa.eu/en/news/ema-recommends-approval-adapted-nuvaxovid-covid-19-vaccine-targeting-omicron-xbb15 72.78.209.27 (talk) 16:32, 3 November 2023 (UTC)

estimate

 * vaccine is generally considered effective if the estimate is ≥50% with a >30% lower limit of the 95% confidence interval.

Estimate of what exactly? —Tamfang (talk) 01:01, 10 November 2023 (UTC)

Update
There should be some updates possible from https://www.ema.europa.eu/en/medicines/human/EPAR/nuvaxovid and the references in NUVAXOVID: Periodic safety update report assessment 20th June 2022 to 19th December 2022 mentioned on pdf pages 129 to 135 (internal page numbers 97 to 103). There are a few obstacles: (1) the bibliographic details (such as journal, volume, page, DOI) are not given; (2) the 196-page report appears to be scanned, so not text searchable, so efficient searching would need running through an optical character recognition program; (3) whether the report itself counts as WP:MEDRS would have to be checked. Since most of the content of the report appears to be by Novavax itself, it doesn't seem to me that it's independent of the producer. A question on the WP:MEDRS talk page should be able to sort out whether it's acceptable. Finding the sources themselves would be better. Boud (talk) 17:39, 6 December 2023 (UTC)

Wiki Education assignment: PHMD 2040 Service - Learning Fall 2023
— Assignment last updated by CharlesG146 (talk) 01:20, 14 April 2024 (UTC)

"Handling and administration" doesn't say expiration dates for current XBB.1.5 vaccines?
Or the upcoming JN.1 vaccine.

Have some Novavavax XBB.1.5 doses already expired? For example those used by Finland?

https://en.wikipedia.org/wiki/Novavax_COVID-19_vaccine#Handling_and_administration

176.72.71.200 (talk) 12:11, 10 June 2024 (UTC)

2012 is an impossible date, please correct the references
This is now in Wikipedia reference list:

"Summary Basis of Decision (SBD) for Nuvaxovid XBB.1.5". Health Canada. 1 September 2012. Retrieved 24 February 2024.

ee1518 (talk) 14:09, 9 July 2024 (UTC)